1. Home
  2. BNR vs FEMY Comparison

BNR vs FEMY Comparison

Compare BNR & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNR
  • FEMY
  • Stock Information
  • Founded
  • BNR 2014
  • FEMY 2004
  • Country
  • BNR China
  • FEMY United States
  • Employees
  • BNR N/A
  • FEMY N/A
  • Industry
  • BNR Medical Specialities
  • FEMY Medical/Dental Instruments
  • Sector
  • BNR Health Care
  • FEMY Health Care
  • Exchange
  • BNR Nasdaq
  • FEMY Nasdaq
  • Market Cap
  • BNR 29.1M
  • FEMY 28.3M
  • IPO Year
  • BNR 2020
  • FEMY 2021
  • Fundamental
  • Price
  • BNR $3.16
  • FEMY $0.95
  • Analyst Decision
  • BNR
  • FEMY Strong Buy
  • Analyst Count
  • BNR 0
  • FEMY 3
  • Target Price
  • BNR N/A
  • FEMY $8.67
  • AVG Volume (30 Days)
  • BNR 38.8K
  • FEMY 450.2K
  • Earning Date
  • BNR 06-06-2025
  • FEMY 08-07-2025
  • Dividend Yield
  • BNR N/A
  • FEMY N/A
  • EPS Growth
  • BNR N/A
  • FEMY N/A
  • EPS
  • BNR N/A
  • FEMY N/A
  • Revenue
  • BNR $72,112,038.00
  • FEMY $1,699,232.00
  • Revenue This Year
  • BNR $136.32
  • FEMY $231.84
  • Revenue Next Year
  • BNR N/A
  • FEMY $245.28
  • P/E Ratio
  • BNR N/A
  • FEMY N/A
  • Revenue Growth
  • BNR 0.53
  • FEMY 61.97
  • 52 Week Low
  • BNR $2.18
  • FEMY $0.69
  • 52 Week High
  • BNR $7.90
  • FEMY $1.80
  • Technical
  • Relative Strength Index (RSI)
  • BNR 48.34
  • FEMY 55.75
  • Support Level
  • BNR $3.06
  • FEMY $0.85
  • Resistance Level
  • BNR $3.50
  • FEMY $1.04
  • Average True Range (ATR)
  • BNR 0.36
  • FEMY 0.08
  • MACD
  • BNR -0.04
  • FEMY 0.02
  • Stochastic Oscillator
  • BNR 20.16
  • FEMY 64.48

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: